At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
BMN 111drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia
In Brief
A Phase 2 clinical trial evaluating BMN 111 for Achondroplasia. Completed, enrolled 35 participants across 9 sites in 4 countries.
Detailed Summary
This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAchondroplasia
CountriesAustralia, France, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedFeb 2014
Primary CompletionOct 2017
TodayJul 2026
First PostedFeb 5, 2014
Enrollment StartJan 13, 2014
Primary CompletionOct 2, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.4 years ago
Interventions
BMN 111drug
BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.